- Home
- SVRE vs XRTX Comparison
SVRE vs XRTX Comparison
Compare SVRE & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVRE | XRTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Israel | Canada |
| Employees | 35 | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SVRE | XRTX |
|---|---|---|
| Price | $2.48 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 540.3K | 9.9K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,793.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.35 |
| 52 Week High | $6.30 | $3.60 |
Technical Indicators
Market Signals| Indicator | SVRE | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.10 | 41.83 |
| Support Level | $0.88 | $2.02 |
| Resistance Level | $3.18 | $2.40 |
| Average True Range (ATR) | 0.64 | 0.13 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 15.46 | 18.63 |
Price Performance
Historical ComparisonAbout SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.